Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS's Reblozyl Data Supports Adding Less Severe Patients To Label

Executive Summary

Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.

You may also be interested in...



BMS Forgoes Thalassemia Label Expansion Revenues For Rebozyl

The firm was unable to respond to the US FDA’s questions on Reblozyl’s risk-benefit profile in an expanded beta-thalassemia setting and will now focus label expansion efforts elsewhere.  

Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028. 

Acceleron To Be Next M&A Target With Rumored $11bn Deal

The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel